文献速递肾癌与肾肿瘤

纳武利尤单抗联合卡博替尼对比帕博利珠单抗联合阿昔替尼治疗晚期肾细胞癌的匹配调整间接比较

A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
PubMed 文献 · Eur Urol Oncol · 2023-02-25

本研究基于CheckMate 9ER试验的纳武利尤单抗联合卡博替尼患者个体数据与KEYNOTE-426试验已发表的帕博利珠单抗联合阿昔替尼数据,通过匹配调整间接比较评估一线治疗晚期肾细胞癌的疗效与健康相关生活质量。结果显示纳武利尤单抗联合卡博替尼较帕博利珠单抗联合阿昔替尼显著改善无进展生存期(HR 0.70 [95%CI 0.53-0.93];p=0.01)并显著降低确认的健康相关生活质量恶化风险(HR 0.48 [95%CI 0.34-0.69]),总生存期相似(HR 0.99 [95%CI 0.67-1.44];p=0.94)。

要点

  • 匹配调整后,纳武利尤单抗联合卡博替尼较帕博利珠单抗联合阿昔替尼显著改善无进展生存期(HR 0.70 [95%CI 0.53-0.93];p=0.01)。
  • 纳武利尤单抗联合卡博替尼较帕博利珠单抗联合阿昔替尼显著降低确认的健康相关生活质量恶化风险(FACT-KSI-DRS:HR 0.48 [95%CI 0.34-0.69])。
  • 两方案总生存期相似(HR 0.99 [95%CI 0.67-1.44];p=0.94),客观缓解率差异未达统计学显著(差值 8.4% [95%CI -1.7 至 18.4];p=0.10)。

核心结论

  • 作为晚期肾细胞癌一线治疗,纳武利尤单抗联合卡博替尼较帕博利珠单抗联合阿昔替尼显著改善无进展生存期和健康相关生活质量。

研究设计与样本

  • 匹配调整间接比较:纳武利尤单抗联合卡博替尼采用CheckMate 9ER试验患者个体数据,帕博利珠单抗联合阿昔替尼采用KEYNOTE-426试验已发表数据,以舒尼替尼为共同锚点,将CheckMate 9ER数据重新加权以匹配KEYNOTE-426报告的关键基线特征。

主要发现

  • 匹配调整后,纳武利尤单抗联合卡博替尼较帕博利珠单抗联合阿昔替尼显著改善无进展生存期(HR 0.70 [95%CI 0.53-0.93];p=0.01)。
  • 纳武利尤单抗联合卡博替尼较帕博利珠单抗联合阿昔替尼显著降低确认的健康相关生活质量恶化风险(FACT-KSI-DRS:HR 0.48 [95%CI 0.34-0.69])。
  • 两治疗间总生存期相似(HR 0.99 [95%CI 0.67-1.44];p=0.94)。
  • 纳武利尤单抗联合卡博替尼较帕博利珠单抗联合阿昔替尼客观缓解率数值更高(差值 8.4% [95%CI -1.7 至 18.4];p=0.10)。
  • 纳武利尤单抗联合卡博替尼较帕博利珠单抗联合阿昔替尼缓解持续时间数值更长(HR 0.79 [95%CI 0.47-1.31];p=0.36)。

关键数值与推荐

  • 纳武利尤单抗 240 mg 每2周联合卡博替尼 40 mg 每日一次。
  • 帕博利珠单抗 200 mg 每3周联合阿昔替尼 5 mg 每日两次(初始剂量)。

临床怎么用

  • 作者认为本分析进一步增加了对这两种方案相对获益的认识,有助于医生和患者的治疗决策。

局限性

  • 需要使用随访时间更长的数据进行比较研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The comparative efficacy and health-related quality of life (HRQoL) outcomes of nivolumab plus cabozantinib versus pembrolizumab plus axitinib as first-line treatments for advanced renal cell carcinoma (aRCC) have not been assessed in head-to-head trials. OBJECTIVE: To assess the efficacy and HRQoL outcomes of nivolumab plus cabozantinib versus pembrolizumab plus axitinib. DESIGN, SETTING, AND PARTICIPANTS: Patient-level data for nivolumab plus cabozantinib from the CheckMate 9ER trial and published data for pembrolizumab plus axitinib from the KEYNOTE-426 trial were used. CheckMate 9ER data were reweighted to match the key baseline characteristics as reported in KEYNOTE-426. INTERVENTION: Nivolumab (240 mg every 2 wk) plus cabozantinib (40 mg once daily) and pembrolizumab (200 mg every 3 wk) plus axitinib (5 mg twice daily, initially). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Hazard ratios (HRs) for progression-free survival (PFS), duration of response, overall survival (OS), and deterioration in HRQoL were assessed using weighted Cox proportional-hazard models, with sunitinib as a common anchor. Objective response rates (ORRs) and changes in HRQoL scores from baseline were assessed as difference-in-differences for the two treatments relative to sunitinib. RESULTS AND LIMITATIONS: After balancing patient characteristics between the trials, nivolumab plus cabozantinib was associated with significantly improved PFS (HR [95% confidence interval {CI}] 0.70 [0.53-0.93]; p = 0.01) and a significantly decreased risk of confirmed deterioration in HRQoL (Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms: HR [95% CI] 0.48 [0.34-0.69]) versus pembrolizumab plus axitinib. OS was similar between treatments (HR [95% CI] 0.99 [0.67-1.44]; p = 0.94). Nivolumab plus cabozantinib was associated with numerically greater ORRs (difference-in-difference [95% CI] 8.4% [-1.7 to 18.4]; p = 0.10) and longer duration of response (HR [95% CI] 0.79 [0.47-1.31]; p = 0.36) than pembrolizumab plus axitinib. Comparative studies using data with a longer duration of follow-up are warranted. CONCLUSIONS: Nivolumab plus cabozantinib significantly improved PFS and HRQoL compared with pembrolizumab plus axitinib as first-line treatment for aRCC. PATIENT SUMMARY: This study was conducted to indirectly compare the results of two immunotherapy-based combinations-nivolumab plus cabozantinib versus pembrolizumab plus axitinib-for patients who have not received any treatment for advanced renal cell carcinoma. Patients who received nivolumab plus cabozantinib had a significant improvement in the length of time without worsening of their disease and in their perceived physical and mental health compared with pembrolizumab plus axitinib; patients remained alive for a similar length of time from the start of either treatment. This analysis further adds to our current knowledge of the relative benefits of these two treatment regimens and will help with physician and patient treatment decisions.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. McGregor B, Geynisman DM, Burotto M, et al. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. Eur Urol Oncol. 2023. PMID: 36842942. doi:10.1016/j.euo.2023.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。